Videos

MediFind's Patrick Howie examines the consolidation of resources during pandemics amid concerns that funding will not return to other areas of health research.

What we've seen non-immunized communities do for previously eradicated outbreaks.

Incredible resources and effort have been put into the COVID-19 response, but other infectious disease priorities have also been displaced. Patrick Howie, CEO of a firm which aggregates clinical analysis and data, explains.

University of Maryland professor of medical technology answers where limited testing resources ought to be directed given pandemic supply issues.

University of Maryland professor of medical technology explains the ways speed and accuracy are weighed when testing is deployed to detect COVID-19.

A discussion with an Ohio State investigator on early CMR findings among young athletes.

Robert H. Christenson, PhD, University of Maryland, outlines the incentives for how SARS-CoV-2 testing reagents are acquired by institutions.

Robert H. Christenson, PhD, outlines the ways SARS-CoV-2 transmission is prevented during testing, how testing materials are acquired, and more.

A clinical-stage immunology company has an investigational therapy looking to target the tumor necrosis factor cytokine.

At a time when schools and college campuses have reopened, an expert discusses adolescents' trends in spreading COVID-19 more easily, and the lack of testing available to them.

How children and adolescents contract, spread, and suffer through the virus differently than other age groups.

Rinki Varindani Desai shares some of the challenges COVID-19 patients with lung injury have faced with Medicare after leaving the hospital.

Dysphagia specialist Rinki Varindani Desai shares her perspective on how COVID-19 has impacted her work and patients.

A team at UCSF has created a model which estimates how many pediatric cases are going unnoticed in any US county at any time.

Heat Biologics CEO Jeff Wolf talks with Contagion about the firm's effort to develop a vaccine for the coronavirus which can potentially be administered for some seniors by taking advantage of prior immune mechanisms.

One effort to develop a SARS-CoV-2 vaccine focuses on combining antibody and T cell immunity, using a gp96 protein based technology.

John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at USP, discusses the recent report of SARS-CoV-2 reinfection.

John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at US Pharmacopeia, explains the fundamentals of convalescent plasma treatment for COVID-19.

Bhopal’s recent article, COVID-19 Zugzwang, was published in Public Health in Practice.

John F. Kokai-Kun, PhD, explains the supply chain and logistical issues limiting the scale of monoclonal antibody treatment.

John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at US Pharmacopeia, explains the fundamentals of monoclonal antibody treatment.

Martin Kulldorff, PhD, explains that masks can't replace social distancing for those at highest risk for severe COVID-19.

Brad Spellberg, MD, explains how real progress can be made to a debted system with worsened rates of user health.

Martin Kulldorff, PhD, answers whether an age based coronavirus strategy would worsen the pandemic's impact on workers and minority racial groups.

John Johnson, lead for Ebola vaccination with MSF France, describes the "ring strategy" used in controlling several infectious disease threats.

Martin Kulldorff, PhD, takes a total social health perspective on the global use of mass quarantines as a primary COVID-19 control strategy.

Brad Spellberg, MD, discusses how the subspecialty lost "ownership" of its opportunities for pattented prescribing and referral years ago.

An infectious disease chief medical officer discusses the cracks in US healthcare exposed by the pandemic.